Article Figures & Data
Figures
- Figure 1.
Flow chart of the study procedure. PD: Progressive disease; EGFR-TKI: epidermal growth factor receptor-tyrosine kinase inhibitor.
- Figure 2.
Number of progressive lesions in PD cases after initial EGFR-TKI therapy. CSF: Cerebrospinal fluid; PD: progressive disease; EGFR: epidermal growth factor receptor; TKI: tyrosine kinase inhibitor. “Others” include the kidney, spleen, skin, ascites, and thyroid gland.
- Figure 3.
Progression-free survival after initial EGFR-TKI therapy, based on the T790M status.
- Figure 4.
Association between rebiopsy site and T790M status.
Tables
In this issue
Jump to section
Related Articles
Cited By...
- Relationship Between Osimertinib Concentration and Clinical Response in Japanese Patients With Non-small Cell Lung Cancer
- Real-world Afatinib Outcomes in Advanced Non-small Cell Lung Cancer Harboring EGFR Mutations
- Which Is Better EGFR-TKI Followed by Osimertinib: Afatinib or Gefitinib/Erlotinib?
- Comparison of PNA Clamping-assisted Fluorescence Melting Curve Analysis and PNA Clamping in Detecting EGFR Mutations in Matched Tumor Tissue, Cell Block, Pleural Effusion and Blood of Lung Cancer Patients With Malignant Pleural Effusion